KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Total Non-Current Liabilities: 2015-2024

Historic Total Non-Current Liabilities for BeOne Medicines (ONC) over the last 10 years, with Dec 2024 value amounting to $373.8 million.

  • BeOne Medicines' Total Non-Current Liabilities rose 207.16% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 207.16%. This contributed to the annual value of $373.8 million for FY2024, which is 18.36% down from last year.
  • Per BeOne Medicines' latest filing, its Total Non-Current Liabilities stood at $373.8 million for FY2024, which was down 18.36% from $457.8 million recorded in FY2023.
  • In the past 5 years, BeOne Medicines' Total Non-Current Liabilities registered a high of $803.4 million during FY2021, and its lowest value of $373.8 million during FY2024.
  • For the 3-year period, BeOne Medicines' Total Non-Current Liabilities averaged around $453.0 million, with its median value being $457.8 million (2023).
  • As far as peak fluctuations go, BeOne Medicines' Total Non-Current Liabilities soared by 102.80% in 2020, and later slumped by 34.35% in 2022.
  • BeOne Medicines' Total Non-Current Liabilities (Yearly) stood at $656.3 million in 2020, then rose by 22.41% to $803.4 million in 2021, then plummeted by 34.35% to $527.4 million in 2022, then decreased by 13.19% to $457.8 million in 2023, then dropped by 18.36% to $373.8 million in 2024.